NCT02757209

Comparative Study on Usability of Inhaler Devices in Adults With Asthma or COPD

STUDY NUMBER: PMC-101-APT Usability and Adherence of Spiromax® Inhaler Device, Turbohaler® and Diskus® Inhaler Devices for Fixed Combination of Corticosteroid/Long-acting beta2- Agonist, in Adults With Asthma or COPD
Consorzio Futuro in Ricerca·ClinicalTrials.gov·device·Device trialCompleted
View on ClinicalTrials.gov
Study focus
Disease/Condition
Asthma,COPD
Drug/Device/Intervention
Spiromax (budesonide/formoterol)
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Consorzio Futuro in Ricerca
Location
Cassano delle Murge,Ferrara,Tradate, Italy
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2016
End date
Jan 01, 2018
Enrollment
84 participants
Primary outcome

Usability of Spiromax , Turbuhaler and Diskus devices

Summary

This is a randomized, multi-center, active-controlled, repeated measures design study in male
 and female patients 60 years of age and older with persistent asthma or COPD.
 
 Study will be conducted in 4 Italian University/Hospital Centers: Ferrara, Parma, Cassano
 delle Murge (Ba), Tradate.
 
 The primary efficacy parameter of the study is inhaler device usability (expressed as total
 number of repeated attempts required to achieve optimal use).

ICD-10 classifications
AsthmaAsthma, unspecifiedNonallergic asthmaMixed asthmaOther chronic obstructive pulmonary disease
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT02757209
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT02757209 through Pure Global AI's free database. This phase not specified trial is sponsored by Consorzio Futuro in Ricerca and is currently Completed. The study focuses on Asthma,COPD. Target enrollment is 84 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.